Mergers & AcquisitionsMedium•5 November 2026•
1 min read
AstraZeneca Proposes $10 Billion Acquisition of Rhythm Pharmaceuticals
Key Facts
1AstraZeneca has reportedly made a non-binding offer to acquire Rhythm Pharmaceuticals for approximately $10 billion.
2The proposed offer values Rhythm Pharmaceuticals at up to $134 per share.
AstraZeneca has reportedly made a non-binding offer to acquire Rhythm Pharmaceuticals for approximately $10 billion. Benzinga reported that the proposed offer values Rhythm Pharmaceuticals at up to $134 per share, as AstraZeneca seeks to bolster its rare disease portfolio.
RYTM closed at $110.68 on November 4, 2026, while AZN closed at $189.01 on the same date. The acquisition is aimed at expanding AstraZeneca's presence and treatment offerings within the rare disease sector.